Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with locally advanced or metastatic non-small cell lung cancer with KRAS G12C detected by an FDA-approved test, after at least one prior systemic treatment.
LAMPGEN ANALYSIS
Why it matters
The original approval translates a specific KRAS substitution into a treatment selection criterion.
What research teams should watch
Confirm the G12C result and prior systemic line, and document liver safety follow-up and dose modifications.
PRIMARY RECORDS